Bicara Therapeutics (BCAX) Competitors $24.01 +0.33 (+1.39%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesSEC FilingsTrends BCAX vs. BBIO, BHVN, ACLX, CRNX, OGN, RARE, IMVT, CYBN, IBRX, and ADMAShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include BridgeBio Pharma (BBIO), Biohaven (BHVN), Arcellx (ACLX), Crinetics Pharmaceuticals (CRNX), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Immunovant (IMVT), Cybin (CYBN), ImmunityBio (IBRX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. BridgeBio Pharma Biohaven Arcellx Crinetics Pharmaceuticals Organon & Co. Ultragenyx Pharmaceutical Immunovant Cybin ImmunityBio ADMA Biologics BridgeBio Pharma (NASDAQ:BBIO) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends. Is BBIO or BCAX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -207.11%. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-207.11% N/A -76.71% Bicara Therapeutics N/A N/A N/A Does the media refer more to BBIO or BCAX? In the previous week, BridgeBio Pharma had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 1 mentions for BridgeBio Pharma and 0 mentions for Bicara Therapeutics. BridgeBio Pharma's average media sentiment score of 0.20 beat Bicara Therapeutics' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Overall Sentiment BridgeBio Pharma Neutral Bicara Therapeutics Neutral Do insiders & institutionals hold more shares of BBIO or BCAX? 99.8% of BridgeBio Pharma shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate BBIO or BCAX? BridgeBio Pharma currently has a consensus target price of $47.50, indicating a potential upside of 86.42%. Bicara Therapeutics has a consensus target price of $41.00, indicating a potential upside of 70.76%. Given BridgeBio Pharma's higher possible upside, equities analysts clearly believe BridgeBio Pharma is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor BBIO or BCAX? BridgeBio Pharma received 158 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 70.43% of users gave BridgeBio Pharma an outperform vote. CompanyUnderperformOutperformBridgeBio PharmaOutperform Votes16270.43% Underperform Votes6829.57% Bicara TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Which has better valuation and earnings, BBIO or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$219.12M21.86-$643.20M-$2.63-9.69Bicara TherapeuticsN/AN/AN/AN/AN/A SummaryBridgeBio Pharma beats Bicara Therapeutics on 8 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / BookN/A5.324.665.02Net IncomeN/A$153.56M$119.06M$225.46M7 Day Performance6.71%0.11%0.80%0.37%1 Month Performance3.49%15.22%5.65%3.57%1 Year PerformanceN/A41.14%36.76%29.44% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics1.6508 of 5 stars$24.01+1.4%$41.00+70.8%N/A$1.24BN/A0.0032Positive NewsBBIOBridgeBio Pharma4.5444 of 5 stars$24.44+2.5%$47.50+94.4%-4.4%$4.57B$219.12M-9.29400Upcoming EarningsBHVNBiohaven2.6476 of 5 stars$51.78-2.0%$61.92+19.6%+72.5%$4.57B$462.51M-5.66239ACLXArcellx1.4875 of 5 stars$84.99+0.8%$89.75+5.6%+150.6%$4.55B$144.75M-81.72130Analyst ForecastShort Interest ↑News CoverageCRNXCrinetics Pharmaceuticals3.052 of 5 stars$57.15-1.4%$68.55+19.9%+91.8%$4.51B$1.39M-15.12210Negative NewsOGNOrganon & Co.4.7 of 5 stars$17.46+1.7%$21.33+22.2%+23.2%$4.49B$6.26B4.4910,000Dividend AnnouncementNews CoverageRAREUltragenyx Pharmaceutical4.1907 of 5 stars$53.07-1.4%$85.08+60.3%+41.5%$4.41B$481.30M-7.271,276Upcoming EarningsIMVTImmunovant2.898 of 5 stars$29.95-0.9%$48.10+60.6%-12.2%$4.38BN/A-15.52120CYBNCybin1.8174 of 5 stars$10.64+2.2%$50.50+374.6%N/A$4.37BN/A-1.7550IBRXImmunityBio0.8202 of 5 stars$6.17+16.0%$4.75-23.0%+62.5%$4.30B$620,000.00-6.36590Gap UpHigh Trading VolumeADMAADMA Biologics2.6103 of 5 stars$16.43+3.9%$15.50-5.7%+450.3%$3.81B$330.24M117.36530Upcoming EarningsShort Interest ↓Gap Up Related Companies and Tools Related Companies BBIO Competitors BHVN Competitors ACLX Competitors CRNX Competitors OGN Competitors RARE Competitors IMVT Competitors CYBN Competitors IBRX Competitors ADMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCAX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
